NCT02147431 is a Phase 1 clinical trial of semaglutide in Diabetes, sponsored by Novo Nordisk A/S.

Who is sponsoring NCT02147431?

NCT02147431 is sponsored by Novo Nordisk A/S.

What drugs are being tested in NCT02147431?

Interventions in NCT02147431: semaglutide, placebo.

What condition does NCT02147431 study?

NCT02147431 studies Diabetes, Diabetes Mellitus, Type 2.

Is NCT02147431 still recruiting?

NCT02147431 is currently completed. Last updated 13 August 2018.

Last reviewed 2018-08-13 · How we verify

NCT02147431

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes

Completed Phase 1 Last updated 13 August 2018

What this trial tests

Phase 1 trial testing semaglutide in Diabetes in 38 participants. Completed in 20 May 2015.

Timeline

21 May 2014

Primary endpoint
20 May 2015

20 May 2015

Quick facts

Lead sponsor	Novo Nordisk A/S
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	treatment
Enrollment	38
Start date	21 May 2014
Primary completion	20 May 2015
Estimated completion	20 May 2015
Sites	1 location across Austria

Drugs / interventions tested

semaglutide (semaglutide) — full drug profile →
placebo

Conditions studied

Diabetes — all drugs for Diabetes →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Novo Nordisk A/S — full company profile →

Who can join

Adults 18 to 64, any sex, with Diabetes or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial is conducted in Europe. The aim of this trial is to investigate the effect of semaglutide on hypoglycaemic counter-regulation compared to placebo in subjects with type 2 diabetes.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes.
Mahapatra MK, Karuppasamy M, Sahoo BM. · · 2022 · cited 92× · PMID 34993760 · DOI 10.1007/s11154-021-09699-1
Population Pharmacokinetics of Semaglutide for Type 2 Diabetes.
Overgaard RV, Delff PH, Petri KCC, Anderson TW, et al · · 2019 · cited 28× · PMID 30788808 · DOI 10.1007/s13300-019-0581-y
Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial.
Korsatko S, Jensen L, Brunner M, Sach-Friedl S, et al · · 2018 · cited 24× · PMID 29893488 · DOI 10.1111/dom.13422
Abstracts of 52nd EASD Annual Meeting.
· 2016 · cited 6× · PMID 27539147 · DOI 10.1007/s00125-016-4046-9
The Effect of Semaglutide on Pancreatic β-Cell Function in Adults with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Abusedera O, Sherif J, Smida M, Fredericks S. · · 2025 · PMID 41464636 · DOI 10.3390/jcm14248734

Verify or expand the search:

Other trials of semaglutide

Trials testing the same drug.

NCT07485062 — Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes · Phase 4 · not yet recruiting
NCT07523633 — Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder · Phase 2 · recruiting
NCT07466017 — A Study of CS060380 Tablets in Patients With MASH and Obesity · Phase 2 · recruiting
NCT06975111 — Focusing on the Menopausal Transition to Improve Mid-Life Women's Health · Phase 2, PHASE3 · recruiting
NCT07213466 — Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder · Phase 4 · recruiting

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Novo Nordisk A/S trials

Trials by the same sponsor.

NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02147431 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
Last refreshed: 13 August 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02147431.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing